menu

Metastatic Breast Cancer: Applying Real-World Evidence to Enhance Shared Decision-Making

Be part of the knowledge.™
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Metastatic Breast Cancer: Applying Real-World Evidence to Enhance Shared Decision-Making

3 episodes
0.75 program credits
43m
MinuteCE®
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Program Post-Test
Program Post-Test Completed
0.75 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Episodes
Presenters
Documents
Comments

  • Overview

    The introduction of cyclin-dependent kinase (CDK) 4/6 inhibitors has drastically changed the treatment landscape of hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer. In clinical studies, combination regimens with CDK4/6 inhibitors consistently double progression-free survival compared to endocrine therapy alone. The impact on overall survival data, however, has been less consistent thus far, with some agents showing a greater benefit than others. This program discusses the real-world survival benefit and tolerability of CDK 4/6 inhibitors in patients with HR+/HER2- breast cancer. Clinicians will gain a broader understanding of how these therapies work in patients and obtain access to a patient education tool that will help inform shared decision-making between patients and providers. 

    Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.

  • Target Audience

    This activity has been designed to meet the educational needs of the interprofessional team, including medical oncologists, nurses, pharmacists, as well as other clinicians, involved in the management of patients with HR+/HER2- metastatic breast cancer.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Evaluate real-world evidence of CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer as it relates to clinical trial evidence
    • Apply real-world evidence to shared decision-making conversations with patients regarding the choice of CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer

  • Accreditation Statement

    To support the improvement of patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and TotalCME, Inc. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) for providing continuing education to healthcare teams.

    This activity was planned by GLC and TotalCME, Inc. for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit(s) for completing this activity.

  • Faculty Disclosure of Commercial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all educational programs. 

    The following disclosures have been made by the faculty of this educational event:

    Hope S. Rugo, MD, FASCO receives research funds from Astellas Pharma Inc., AstraZeneca, Daiichi Sankyo, Inc., F. Hoffmann-La Roche AG/Genentech, Inc., Gilead Sciences, Inc., GlaxoSmithKline, Lilly, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, OBI Pharma, Pfizer, Pionyr Immunotherapeutics, Sermonix Pharmaceuticals Inc., Taiho Oncology, Inc., and Veru Inc; receives consulting fees from Puma, NAPO, Blueprint, and Scorpion Therapeutics; and receives other funding from Merck, Astra Zeneca and Gilead.   

    Adam M. Brufsky, MD, PhD receives honoraria and advisory board fees from Roche, Celgene, AstraZeneca, Seattle Genetics, Daiichi Sankyo, Athenex, Lilly, Merck Sharp & Dohme, Gilead, Novartis, Eisai, Pfizer, Samsung, GE, Coherus, SeaGen, Puma; and receives research funding from Roche, AstraZeneca, Merk Charp & Dohme, Novartis, Lilly, Gilead, and Puma. 

  • Planners and Managers Disclosure List

    The following planners/reviewers/managers have disclosed:

    Megan Reimann, PharmD, BCOP, planner for this educational event, has no relevant financial relationships with ineligible companies.

    William Mencia, MD, FACEHP, CHCP, reviewer for this educational event, has no relevant financial relationships with ineligible companies.

    TotalCME, Inc. planners and managers have no relevant commercial relationships to disclose.

    All the relevant financial relationships for these individuals have been mitigated.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and TotalCME, Inc. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • Acknowledgment

    This activity is supported by an independent educational grant from Pfizer Inc.

    Jointly provided by Global Learning Collaborative (GLC) and TotalCME, Inc.

  • Fee Statement

    This activity is FREE to all participants.

  • Instructions for Completion

    During the period 2/10/2023 through 2/10/2024, registered participants wishing to receive continuing education credit for this activity must follow these steps:

    1. Read the learning objectives and faculty disclosures.
    2. Answer a pre-program question.
    3. View the program.
    4. Complete the post-test with a score of 100%. 
    5. Complete activity evaluation.
    6. Apply for credit and either bank your credits or print your certificate.


    For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Presenters
Documents
What Is the Latest Real-World Evidence for CDK4/6 Inhibitors in Metastatic HR+ Breast Cancer?.pptx
How Does Real-World Evidence Expand Understanding of CDK4/6 Inhibitor Use in Special Populations With HR+/HER2- Metastatic Breast Cancer?.pptx

Facebook Comments

Schedule21 Sep 2023
PrevNext

Program Chapters

Segment Chapters

Playlist:

Recommended